Backgrounds/Aims: Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) has generated controversy due to high morbidity and mortality. We present our series of patients with 30-40% parenchymal transection and minimal hilar dissection. Methods: Patients who had partial ALPPS between April 2015 and April 2016 were included. Patients with colorectal liver metastases (CRLM) had their future liver remnants (FLR) cleared with metastasectomies. The liver was divided along the future line of transection to 30-40%, right portal vein was stapled and divided without extensive hilar dissection, with minimal handling of right liver, which was not mobilised. We preserved the middle hepatic vein. Data were collected prospectively for hypertrophy of the FLR, morbidity and mortality. Results: Among the 8 patients (age 25-68) investigated, one patient with cholangiocarcinoma had portal vein embolization prior to partial ALPPS. All patients completed two stages with adequate FLR hypertrophy at a median of 28 days. No mortality was found. The median length of stay after stages 1 and 2 was 9 and 9.6 days, respectively. The median increase in FLR was 38%. Conclusions: A limited transection of 30-40%, minimal hilar dissection and longer wait between stages yielded adequate FLR hypertrophy with low morbidity and no mortality. 
INTRODUCTION
Liver resection offers the best chance for long-term survival of patients with colorectal liver metastases (CRLM) and hilar cholangiocarcinoma. A combination of better chemotherapeutic regimens and surgical innovations has increased the resection rates in patients with CRLM.
Several technical limiting factors such as location of the tumor and distribution preclude liver resection. A future liver remnant (FLR) of 20-30% is deemed safe in patients with normal background liver and at least 40% FLR in patients with compromised liver (steatohepatitis, fibrosis, cirrhosis). 1 The techniques that have proved successful in increasing resection rates include neoadjuvant chemotherapy in patients with CRLM, [2] [3] [4] portal vein embolization (PVE), 5 portal vein ligation (PVL), 6 two-stage liver resections, 7 Associating Liver Partition and Portal vein ligation in Staged hepatectomy (ALPPS) 8 and Associating Portal Embolization and Artery Ligation (APEAL). 9 The ALPPS procedure created tremendous interest among liver surgeons because of the pace of liver regeneration that it allowed, enabling completion of the two stages of liver resection within 9 to 11 days. The procedure has yet to be widely adopted mainly due to concerns with increasing morbidity, mortality 10 and potentially higher recurrence rates. 11, 12 We performed the first ALPPS procedure in April 2015 using only partial transection of liver and other technical modifications involving minimal dissection. This approach produced significant hypertrophy of the FLR and we have performed 8 procedures with no mortality and acceptable morbidity. We proceeded to the second stage in all pa- tients after a longer interval than the classical ALPPS.
The aim of this report is to show the feasibility of safe two-stage liver resection via transection of only 30-40% of liver (partial ALPPS). A longer interval between the two procedures may lead to less liver failure.
PATIENTS AND METHODS
In order to describe the modified version of the ALPPS procedure, the first operation is briefly explained below. Using laparotomy, the tumors in the segments 2, 3 and 4b were removed as metastasectomies ( Fig. 2 ) with macroscopically clear margins. The FLR was inadequate.
Cholecystectomy was carried out and the right portal vein (RPV) was ligated with minimal dissection by incising the peritoneum on the right and posterior aspects of the hilum.
The RPV was stapled and divided ( A computed tomography (CT) scan was performed to measure the volume of the FLR 12 days after the first stage procedure and volumes were assessed using standard procedure described below. 13 The CT assessment showed an increase in FLR from We recorded the complications and classified them according to the Clavien-Dindo system. 14 Post-hepatectomy liver failure (PHLF) was classified according to the grades proposed by the International Study Group of Liver Surgery. 15 We followed up patients at 4 weeks after surgery and at 3 monthly intervals. The CT scan of chest abdomen and pelvis was carried out at 3 months, 6 months and a year from the second stage procedure. Recurrence data and mortality were censored at December 2016. able easy access to the second procedure. We left a long polydioxanone (PDS) suture around the hilum as a loop for easy identification of the hilum to facilitate Pringle's maneuver during the second operation.
de Santibañes et al. 16 have described a similar procedure in four patients. However, they did not perform any hilar dissection during the first stage. Instead, they performed intraoperative PVE using the inferior mesenteric vein and designated the procedure as Mini-ALPPS. They claim that the lack of hilar dissection is beneficial for the second stage. We perform minimal hilar dissection and only the right and posterior peritoneum on the hilum is dissected to allow access to the right portal vein, which is stapled.
We have not encountered any difficulties related to this during the second stage. We started to perform the procedure before the Santibanes paper was published, and hence our approach of minimal hilar dissection. This approach also avoids any potential logistic difficulties in performing PVE in the theatre. Li et al. 17 described similar operation of PVE 2 days after the first procedure in patients with tumor involving the hilum.
The advantages of ALPPS include the higher completion rates of the two stages compared with two-stage hepatectomies (TSH). However, critics have shown a poorer long-term outcome in patients undergoing ALPPS compared with TSH. 18 Our study is an observational study and hence prone to many biases. A randomized controlled trial is the only way to compare the long-term outcomes of ALPPS vs. TSH. Although no randomized controlled trial compared ALPPS and TSH, a systematic review and meta-analysis of all the comparative studies showed that the overall survival was not different between the two approaches. ALPPS was associated with higher morbidity and mortality. 19 In addition, higher rates of liver failure followed ALPPS despite volumetric increase in the rem- The median increase in hypertrophy in our patients was 38% (10-78%), which was lower than in classical ALPPS, where the range varied from 58% to 110%. 22 
